Business
Supernus Announces Preliminary Fourth Quarter and Full Year 2021 Financial Results
Preliminary full year 2021 total revenues were $579.8 million; an 11% increase compared to $520.4 million in 2020SPN-830 (apomorphine infusion device) NDA
About this update from Supernus Pharmaceuticals, Inc.
[{"type":"text","content":"Preliminary full year 2021 total revenues were $579.8 million; an 11% increase compared to $520.4 million in 2020SPN-830 (apomorphine infusion device) NDA accepted for review by FDA; PDUFA date early October 2022Completed acquisition of Adamas Pharmaceuticals, Inc. in November 2021; integration well underwayQelbree® continued its growth trajectory, closing the year with 13,380 prescriptions in December 2021 ROCKVILLE, Md., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced preliminary financial results for the fourth quarter and full year of 2021, and associated Company developments. Net Product Sales For full year 2021, preliminary net product sales were $567.5 million, an 11% increase over $509.3 million for the full year 2020. The increase was primarily due to the acquisition of the CNS portfolio of US WorldMeds in June 2020, growth in net product sales of Oxtellar XR®, the launch of Qelbree in the second quarter of 2021, and net product sales of GOCOVRI® (amantadine) from the acquisition of Adamas Pharmaceuticals, Inc. (Adamas) in November 2021. Preliminary fourth quarter 2021 net product sales were $155.0 million, a 10% increase over $140.7 million in the same period in 2020. The increase was primarily due to net product sales of GOCOVRI from the acquisition of Adamas in November 2021, the launch of Qelbree in the second quarter of 2021, and growth in net product sales of Oxtellar XR. Net Product SalesThree Months EndedDecember 31, Twelve Months EndedDecember 31, ($ in millions) 2021 2020 Change % 2021 2020 Change %Trokendi XR®$73.3 $78.5 (7)% $304.8 $319.6 (5)%Oxtellar XR® 28.6 22.7 26 % 110.7 98.7 12 %APOKYN® 25.9 31.2 (17)% 99.2 74.3 34 %GOCOVRI 9.8 — ** 9.8 — **Qelbree 7.2 — ** 9.9 — **Other(1) 10.2 8.3 23 % 33.1 16.7 98 %Net Product Sales$155.0 $140.7 10 % $567.5 $509.3 11 % ___________________________________________ (1) Includes net product sales of MYOBLOC®, XADAGO® and Osmolex ER®. The fourth quarter and full year 2021 revenue results included herein are preliminary and are therefore subject to change. Qelbree Launch Update Total IQVIA prescriptions were 34,328 in the fourth quarter of 2021, an increase of 122% compared to total pres...